首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1983156

胸膜炎治療市場：按治療方法、症狀、患者類型、醫療機構、分銷管道、最終用戶和地區分類

Pleurodynia Treatment Market, By Treatment Modality, By Symptoms, By Patient Type, By Healthcare Setting, By Distribution Channel, By End User, By Geography

出版日期: 2026年02月11日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，胸膜炎治療市場規模將達到 1.611 億美元，到 2033 年將達到 2.4064 億美元。預計從 2026 年到 2033 年，該市場將以 5.9% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	1.611億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	5.90%	2033年市場規模預測：	2.4064億美元

胸膜炎（俗稱流行性肌肉痛或博恩霍爾姆病）是一種主要由克沙奇病毒B引起的病毒感染疾病，其特徵是嚴重的胸部和上腹部疼痛，症狀類似心臟和肺部疾病。這種急性發燒疾病主要影響兒童和青少年，表現為胸壁肌肉和膈肌的劇烈、間歇性疼痛，常伴隨發燒、頭痛和不適。全球胸膜炎治療市場涵蓋了旨在治療疾病的藥物干預、支持療法和診斷解決方案。胸膜炎可自行消退，但會顯著損害身體機能。

治療通訊協定通常包括症狀治療，使用止痛藥、抗發炎藥，重症患者則使用抗病毒藥物。支持性照護包括休息、補充液體和必要的呼吸支持。隨著人們對腸病毒感染疾病的認知不斷提高、診斷能力不斷提升以及標靶治療方法的研發，市場環境正在改變。腸病毒感染與其他呼吸系統和心臟疾病的症狀重疊，為醫療專業人員的準確診斷帶來了挑戰，也推動了對先進診斷工具和治療通訊協定的需求。病毒爆發的日益增多，以及發展中地區醫療基礎設施的改善，持續影響全球市場動態和治療可近性。

市場動態

全球胸膜炎治療市場正經歷顯著成長，這主要得益於醫護人員和患者對腸病毒感染疾病的認知不斷提高。這提高了診斷率，並相應地增加了治療需求。病毒爆發的發生率不斷上升，尤其是在學校和軍事設施等人員密集的場所，持續推高了對有效治療性介入的市場需求。診斷能力的提升，包括先進的分子檢測和照護現場技術，能夠快速識別病原體，有助於及時啟動治療，並推動市場擴張。

新興經濟體醫療保健成本的不斷上漲，以及抗病毒藥物和疼痛管理療法的可近性提高，正在推動不同地區市場的成長。然而，胸膜炎通常會自行消退，且往往無需特殊治療，這可能限制了藥物干預的需求，從而對市場構成重大限制。此外，由於胸膜炎的症狀與心肺疾病相似，誤診仍是一個主要挑戰，導致不當的治療通訊協定和市場效率低下。基層醫療醫師對鑑別診斷技術的認知不足，可能導致病例漏報和不恰當的治療方法。此外，缺乏針對某些腸病毒株的特異性抗病毒療法也限制了治療選擇和市場潛力。

儘管面臨這些挑戰，但針對特定腸病毒作用機制的新型抗病毒化合物的研發，有望帶來突破性的治療方法。遠端醫療平台的擴展為遠距會診和監測提供了契機，這在疫情爆發期間尤其重要。投資研發快速診斷工具蘊藏著巨大的市場機會。特別是，能夠區分胸膜炎與其他胸痛病因的就地檢驗解決方案，有望最終改善患者預後並加速市場滲透。

本次調查的主要特點。

本報告對全球胸膜炎治療市場進行了詳細分析，顯示了以 2025 年為基準年，預測期（2026-2033 年）的市場規模和複合年成長率（%）。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球胸膜炎治療市場的主要企業參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球胸膜炎治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第11章競爭格局

AbbVie Inc
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Company
Cipla Ltd
Reddy's Laboratories Ltd
Hoffmann La Roche Ltd
GlaxoSmithKline plc
Johnson &Johnson
Merck &Co., Inc
Novartis AG
Pfizer Inc
Sanofi SA
Sun Pharmaceutical Industries Ltd

第12章分析師建議

機會
分析師意見
Coherent Opportunity Map

第13章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9323

Pleurodynia Treatment Market is estimated to be valued at USD 161.1 Mn in 2026 and is expected to reach USD 240.64 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 161.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.90%	2033 Value Projection:	USD 240.64 Mn

Pleurodynia, commonly referred to as epidemic myalgia or Bornholm disease, represents a viral infection primarily caused by Coxsackievirus B, characterized by intense chest and upper abdominal pain that mimics cardiac or pulmonary conditions. This acute febrile illness predominantly affects children and young adults, presenting with sharp, intermittent pain in the chest wall muscles and diaphragm, often accompanied by fever, headache, and malaise. The global pleurodynia treatment market encompasses pharmaceutical interventions, supportive care therapies, and diagnostic solutions aimed at managing this self-limiting yet debilitating condition.

Treatment protocols typically involve symptomatic management through analgesics, anti-inflammatory medications, and antiviral agents in severe cases, while supportive measures include rest, hydration, and respiratory support when necessary. The market landscape is evolving with increased awareness of enteroviral infections, improved diagnostic capabilities, and the development of targeted therapeutic approaches. Healthcare providers face challenges in accurate diagnosis due to symptom overlap with other respiratory and cardiac conditions, driving demand for enhanced diagnostic tools and treatment protocols. The growing incidence of viral outbreaks, coupled with improved healthcare infrastructure in developing regions, continues to shape market dynamics and treatment accessibility globally.

Market Dynamics

The global pleurodynia treatment market experiences significant growth driven by increasing awareness about enteroviral infections among healthcare professionals and patients, leading to improved diagnosis rates and subsequent treatment demand. Rising incidence of viral outbreaks, particularly in crowded environments such as schools and military facilities, creates sustained market demand for effective therapeutic interventions. Enhanced diagnostic capabilities, including advanced molecular testing and point-of-care diagnostics, enable faster identification of causative agents, promoting timely treatment initiation and driving market expansion.

Growing healthcare expenditure in emerging economies, coupled with improved access to antiviral medications and pain management therapies, contributes to market growth across diverse geographical regions. However, the market faces substantial restraints including the self-limiting nature of pleurodynia, which often resolves without specific treatment, potentially limiting pharmaceutical intervention requirements. Misdiagnosis remains a significant challenge due to symptom similarity with cardiac and pulmonary conditions, leading to inappropriate treatment protocols and market inefficiencies. Limited awareness among primary care physicians about differential diagnosis techniques may result in underreporting and suboptimal treatment approaches. Additionally, the absence of specific antiviral therapies for certain enteroviral strains constrains treatment options and market potential.

Despite these challenges, opportunities emerge through development of novel antiviral compounds targeting specific enteroviral mechanisms, creating potential for breakthrough therapies. Expanding telemedicine platforms offer opportunities for remote consultation and monitoring, particularly valuable in outbreak scenarios. Investment in research and development for rapid diagnostic tools presents significant market opportunities, especially for point-of-care testing solutions that can differentiate pleurodynia from other chest pain etiologies, ultimately improving patient outcomes and market penetration.

Key Features of the Study

This report provides in-depth analysis of the global pleurodynia treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pleurodynia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Ltd, Dr. Reddy's Laboratories Ltd, F. Hoffmann La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc, Novartis AG, Pfizer Inc, Sanofi S.A, and Sun Pharmaceutical Industries Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global pleurodynia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pleurodynia treatment market

Market Segmentation

Treatment Modality Insights (Revenue, USD Mn, 2021 - 2033)
- Pharmacological Therapies
- Analgesics
- Non Steroidal Anti Inflammatory Drugs (NSAIDs)
- Antiviral Agents
- Muscle Relaxants
- Corticosteroids
- Non Pharmacological Therapies
- Physical Therapy
- Pain Management Procedures
- Supportive Care (Rest, Hydration)
- Combination Therapies
- Pharmacological + Non Pharmacological
Symptoms Insights (Revenue, USD Mn, 2021 - 2033)
- Chest Pain
- Fever
- Cough
- Headache
- Sore Throat
- Muscular Aches and Pains
Patient Type Insights (Revenue, USD Mn, 2021 - 2033)
- Adult
- Geriatric
- Pediatric
Healthcare Setting Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital
- Ambulatory/Outpatient Clinics
- Home Healthcare
Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Mn, 2021 - 2033)
- Healthcare Providers
- Hospitals
- Clinics
- Patients/Consumers
Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- AbbVie Inc
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Company
- Cipla Ltd
- Reddy's Laboratories Ltd
- Hoffmann La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc
- Novartis AG
- Pfizer Inc
- Sanofi S.A
- Sun Pharmaceutical Industries Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Pleurodynia Treatment Market, By Treatment Modality
- Global Pleurodynia Treatment Market, By Symptoms
- Global Pleurodynia Treatment Market, By Patient Type
- Global Pleurodynia Treatment Market, By Healthcare Setting
- Global Pleurodynia Treatment Market, By Distribution Channel
- Global Pleurodynia Treatment Market, By End User
- Global Pleurodynia Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global Pleurodynia Treatment Market, By Treatment Modality, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Analgesics
  - Non Steroidal Anti Inflammatory Drugs (NSAIDs)
  - Antiviral Agents
  - Muscle Relaxants
  - Corticosteroids
Non Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Physical Therapy
  - Pain Management Procedures
  - Supportive Care (Rest, Hydration)
Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Pharmacological + Non Pharmacological

5. Global Pleurodynia Treatment Market, By Symptoms, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Chest Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Fever
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Cough
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Headache
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Sore Throat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Muscular Aches and Pains
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Pleurodynia Treatment Market, By Patient Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Pleurodynia Treatment Market, By Healthcare Setting, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Ambulatory/Outpatient Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Home Healthcare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

8. Global Pleurodynia Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

9. Global Pleurodynia Treatment Market, By End User, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Healthcare Providers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Patients/Consumers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

10. Global Pleurodynia Treatment Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hoffmann La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies